Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Short-term exposure of human ovarian follicles to cyclophosphamide metabolites seems to promote follicular activation in vitro.

Lande Y, Fisch B, Tsur A, Farhi J, Prag-Rosenberg R, Ben-Haroush A, Kessler-Icekson G, Zahalka MA, Ludeman SM, Abir R.

Reprod Biomed Online. 2017 Jan;34(1):104-114. doi: 10.1016/j.rbmo.2016.10.005. Epub 2016 Oct 17.

PMID:
27815062
2.

Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.

Calinski DM, Zhang H, Ludeman S, Dolan ME, Hollenberg PF.

Drug Metab Dispos. 2015 Jul;43(7):1084-90. doi: 10.1124/dmd.115.063628. Epub 2015 May 1.

3.

Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients.

Pinto N, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, Im HK, Diskin SJ, London WB, Ludeman SM, Maris JM, Cox NJ, Cohn SL, Dolan ME.

Clin Pharmacol Ther. 2014 Jun;95(6):644-52. doi: 10.1038/clpt.2014.37. Epub 2014 Feb 18.

4.

Labeled oxazaphosphorines for applications in mass spectrometry studies. 2. Synthesis of deuterium-labeled 2-dechloroethylcyclophosphamides and 2- and 3-dechloroethylifosfamides.

Springer JB, Colvin OM, Ludeman SM.

J Labelled Comp Radiopharm. 2014 Feb;57(2):110-4. doi: 10.1002/jlcr.3142. Epub 2013 Dec 5.

PMID:
24307455
5.

Non-invasive monitoring of L-2-oxothiazolidine-4-carboxylate metabolism in the rat brain by in vivo 13C magnetic resonance spectroscopy.

Gamcsik MP, Clark MD, Ludeman SM, Springer JB, D'Alessandro MA, Simpson NE, Pourdeyhimi R, Johnson CB, Teeter SD, Blackband SJ, Thelwall PE.

Neurochem Res. 2011 Mar;36(3):443-51. doi: 10.1007/s11064-010-0362-5. Epub 2010 Dec 15.

6.

Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.

Pinto N, Ludeman SM, Dolan ME.

Pharmacogenomics. 2009 Dec;10(12):1897-903. doi: 10.2217/pgs.09.134. Review.

7.

Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice.

Emmenegger U, Shaked Y, Man S, Bocci G, Spasojevic I, Francia G, Kouri A, Coke R, Cruz-Munoz W, Ludeman SM, Colvin OM, Kerbel RS.

Mol Cancer Ther. 2007 Aug;6(8):2280-9. Epub 2007 Aug 1.

8.

Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Hansen RJ, Ludeman SM, Paikoff SJ, Pegg AE, Dolan ME.

DNA Repair (Amst). 2007 Aug 1;6(8):1145-54. Epub 2007 May 7.

9.

1,3- vs 1,5-intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards.

Springer JB, Chang YH, Koo KI, Colvin OM, Colvin ME, Dolan ME, Delaney SM, Flowers JL, Ludeman SM.

Chem Res Toxicol. 2004 Sep;17(9):1217-26.

PMID:
15377155
10.

Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy.

Dreher MR, Raucher D, Balu N, Michael Colvin O, Ludeman SM, Chilkoti A.

J Control Release. 2003 Aug 28;91(1-2):31-43.

PMID:
12932635
11.

Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells.

Smith SM, Ludeman SM, Wilson LR, Springer JB, Gandhi MC, Dolan ME.

Cancer Chemother Pharmacol. 2003 Oct;52(4):291-302. Epub 2003 Jul 4.

PMID:
12845477
12.

Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity?

Ludeman SM, Gamcsik MP.

Cancer Treat Res. 2002;112:177-97. Review. No abstract available.

PMID:
12481717
13.
14.

Exposure to a deuterated analogue of phenylbutyrate retards S-phase progression in HT-29 colon cancer cells.

Clarke KO, Ludeman SM, Springer JB, Colvin OM, Lea MA, Harrison LE.

J Pharm Sci. 2002 Apr;91(4):1054-64.

PMID:
11948544
15.

Modified guanines representing O(6)-alkylation by the cyclophosphamide metabolites acrolein and chloroacetaldehyde: synthesis, stability, and ab initio studies.

Balu N, Gamcsik MP, Colvin ME, Colvin OM, Dolan ME, Ludeman SM.

Chem Res Toxicol. 2002 Mar;15(3):380-7.

PMID:
11896686
16.

Isophosphoramide Mustard and Its Mechanism of Bisalkylation.

Springer JB, Colvin ME, Colvin OM, Ludeman SM.

J Org Chem. 1998 Oct 16;63(21):7218-7222.

PMID:
11672363
17.

Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.

Ichikawa T, Petros WP, Ludeman SM, Fangmeier J, Hochberg FH, Colvin OM, Chiocca EA.

Cancer Res. 2001 Feb 1;61(3):864-8.

18.

Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide.

Flowers JL, Ludeman SM, Gamcsik MP, Colvin OM, Shao KL, Boal JH, Springer JB, Adams DJ.

Cancer Chemother Pharmacol. 2000;45(4):335-44.

PMID:
10755323
20.

The chemistry of the metabolites of cyclophosphamide.

Ludeman SM.

Curr Pharm Des. 1999 Aug;5(8):627-43. Review.

PMID:
10469895
21.

Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity.

Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, Ludeman SM, Smith C.

Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9118-23.

22.

Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity.

Cai Y, Wu MH, Ludeman SM, Grdina DJ, Dolan ME.

Cancer Res. 1999 Jul 1;59(13):3059-63.

23.

Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase.

Friedman HS, Pegg AE, Johnson SP, Loktionova NA, Dolan ME, Modrich P, Moschel RC, Struck R, Brent TP, Ludeman S, Bullock N, Kilborn C, Keir S, Dong Q, Bigner DD, Colvin OM.

Cancer Chemother Pharmacol. 1999;43(1):80-5.

PMID:
9923545
24.

The partitioning of phosphoramide mustard and its aziridinium ions among alkylation and P-N bond hydrolysis reactions.

Shulman-Roskes EM, Noe DA, Gamcsik MP, Marlow AL, Hilton J, Hausheer FH, Colvin OM, Ludeman SM.

J Med Chem. 1998 Feb 12;41(4):515-29.

PMID:
9484502
25.

A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC).

Dong Q, Barsky D, Colvin ME, Melius CF, Ludeman SM, Moravek JF, Colvin OM, Bigner DD, Modrich P, Friedman HS.

Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12170-4.

26.

Effect of stereochemistry on the oxidative metabolism of the cyclophosphamide metabolite aldophosphamide.

Habib AD, Boal JH, Hilton J, Nguyen T, Chang YH, Ludeman SM.

Biochem Pharmacol. 1995 Jul 31;50(3):429-33.

PMID:
7646546
27.

Comparison of the protonation of isophosphoramide mustard and phosphoramide mustard.

Millis KK, Colvin ME, Shulman-Roskes EM, Ludeman SM, Colvin OM, Gamcsik MP.

J Med Chem. 1995 Jun 9;38(12):2166-75.

PMID:
7783148
28.

Quantitation of 4-hydroxycyclophosphamide/aldophosphamide in whole blood.

Anderson LW, Ludeman SM, Colvin OM, Grochow LB, Strong JM.

J Chromatogr B Biomed Appl. 1995 May 19;667(2):247-57.

PMID:
7663697
29.

Assessment of aldehyde dehydrogenase in viable cells.

Jones RJ, Barber JP, Vala MS, Collector MI, Kaufmann SH, Ludeman SM, Colvin OM, Hilton J.

Blood. 1995 May 15;85(10):2742-6.

30.

Oxime derivatives of the intermediary oncostatic metabolites of cyclophosphamide and ifosfamide: synthesis and deuterium labeling for applications to metabolite quantification.

Ludeman SM, Shulman-Roskes EM, Wong KK, Han SY, Anderson LW, Strong JM, Colvin OM.

J Pharm Sci. 1995 Apr;84(4):393-8.

PMID:
7629726
31.

Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy.

Boal JH, Ludeman SM, Ho CK, Engel J, Niemeyer U.

Arzneimittelforschung. 1994 Jan;44(1):84-93.

PMID:
8135883
32.

Protonation of phosphoramide mustard and other phosphoramides.

Gamcsik MP, Ludeman SM, Shulman-Roskes EM, McLennan IJ, Colvin ME, Colvin OM.

J Med Chem. 1993 Nov 12;36(23):3636-45.

PMID:
8246232
33.

Cyclophosphamide resistance in medulloblastoma.

Friedman HS, Colvin OM, Kaufmann SH, Ludeman SM, Bullock N, Bigner DD, Griffith OW.

Cancer Res. 1992 Oct 1;52(19):5373-8.

34.

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.

Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Hurowitz L, DeLisa A, Donehower RC, et al.

Drug Metab Dispos. 1992 Sep-Oct;20(5):706-13.

PMID:
1358575
35.

Carboxyphosphamide: NMR studies of its stability and cell membrane permeability.

Ludeman SM, Ho CK, Boal JH, Sweet EM, Chang YH.

Drug Metab Dispos. 1992 Mar-Apr;20(2):337-8. No abstract available.

PMID:
1352232
36.

31P NMR studies of the kinetics of bisalkylation by isophosphoramide mustard: comparisons with phosphoramide mustard.

Boal JH, Williamson M, Boyd VL, Ludeman SM, Egan W.

J Med Chem. 1989 Aug;32(8):1768-73.

PMID:
2754703
37.

Embryotoxicity of phenyl ketone analogs of cyclophosphamide.

Hales BF, Ludeman SM, Boyd VL.

Teratology. 1989 Jan;39(1):31-7.

PMID:
2718138
38.

Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.

Friedman HS, Colvin OM, Skapek SX, Ludeman SM, Elion GB, Schold SC Jr, Jacobsen PF, Muhlbaier LH, Bigner DD.

Cancer Res. 1988 Aug 1;48(15):4189-95.

40.
41.

Experimental chemotherapy of human medulloblastoma with classical alkylators.

Friedman HS, Colvin OM, Ludeman SM, Schold SC Jr, Boyd VL, Mulhbaier LH, Bigner DD.

Cancer Res. 1986 Jun;46(6):2827-33.

43.

Synthesis of reactive metabolite-analogues of cyclophosphamide for comparisons of NMR kinetic parameters and anticancer screening data.

Ludeman SM, Boyd VL, Regan JB, Gallo KA, Zon G, Ishii K.

Drugs Exp Clin Res. 1986;12(6-7):527-32.

PMID:
3743371
45.

O-imino esters of N,N-bis(2-chloroethyl)phosphorodiamidic acid. Synthesis, X-ray structure determination, and anticancer evaluation.

Ludeman SM, Shao KL, Zon G, Himes VL, Mighell AD, Takagi S, Mizuta K.

J Med Chem. 1983 Dec;26(12):1788-90.

PMID:
6644750
46.

Synthesis and evaluation of 3-halocyclophosphamides and analogous compounds as novel anticancer "pro-prodrugs".

Zon G, Ludeman SM, Ozkan G, Chandrasegaran S, Hammer CF, Dickerson R, Mizuta K, Egan W.

J Pharm Sci. 1983 Jun;72(6):687-91.

PMID:
6875830
47.

Synthesis and study of a spin-labeled cyclophosphamide analogue, 3-(1-oxy-2,2,6,6-tetramethyl-4-piperidinyl)cyclophosphamide.

Tsui FP, Robey FA, Engle TW, Ludeman SM, Zon G.

J Med Chem. 1982 Sep;25(9):1106-10.

PMID:
7131492
48.

O-Methylhydroxylamine as a new trapping reagent for quantitative studies of 4-hydroxycyclophosphamide and aldophosphamide.

Zon G, Ludeman SM, Sweet EM, Egan W, Phillips LR.

J Pharm Sci. 1982 Apr;71(4):443-6.

PMID:
7086655
49.

Synthesis of 3-hydroxycyclophosphamide and studies related to its possible role in the metabolism of cyclophosphamide.

Brandt JA, Ludeman SM, Zon G, Todhunter JA, Egan W, Dickerson R.

J Med Chem. 1981 Dec;24(12):1404-8.

PMID:
7310817

Supplemental Content

Loading ...
Support Center